Development of a novel adenovirus type 4 vector as a promising respiratory vaccine vehicle.

ABSTRACT:

Introduction

Adenovirus (Ad) vectors are widely used for gene delivery, and some of them have been approved for vaccine development. In particular, the recombinant COVID-19 vaccine for inhalation, which was developed using adenovirus type 5 (Ad5), represents a milestone in respiratory immunization. Owing to the high pre-existing immunity (PEI) to Ad5, the development of an adenoviral vector with lower PEI and higher immunogenicity has been explored. However, the majority of the developed novel Ad vectors showed suboptimal immunogenicity compared to Ad5 in animal models.

Method

In this study, we constructed a novel replication-deficient viral vector based on human adenovirus type 4 (Ad4), which has long been used as a live virus vaccine with a favorable safety profile in the

SUBMITTER: Xu J 

PROVIDER: S-EPMC12018414 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature